Talking Tumors: Contemplating Clinical Conundrums in Lung Cancer

We recently traveled to Newton, Massachusetts, for a State of the Science Summit™ on Lung Cancer. Immunotherapy and targeted therapy have become important treatment approaches to consider in advanced non–small cell lung cancer. Although biomarkers such as PD-L1 expression and EGFR mutations have helped refine which patient populations are best suited to each approach, several questions remain. For example, should a patient with newly diagnosed stage IV lung adenocarcinoma whose PD-L1 expression is 90% receive single-agent pembrolizumab or chemoimmunotherapy? Additionally, what is the optimal treatment strategy in a patient with EGFR-mutant non–small cell lung cancer who is progressing on first-line osimertinib?